Octreotide vs Adamax
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Octreotide
Octreotide (Sandostatin) is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid tumors, and VIPomas. It inhibits growth hormone and various GI hormones.
Full details →Adamax
Adamax is a modified version of Semax with an adamantane group attached, designed to enhance its nootropic effects and extend duration of action compared to standard Semax.
Full details →Side-by-Side Comparison
| Aspect | Octreotide | Adamax |
|---|---|---|
| Mechanism | Binds to somatostatin receptors (primarily SSTR2 and SSTR5) to inhibit GH, glucagon, insulin, and gastric secretions. Reduces blood flow to GI tract and inhibits tumor hormone secretion. | Similar to Semax - enhances BDNF expression and modulates dopamine/serotonin systems. The adamantane modification may increase lipophilicity and CNS penetration. |
| Typical Dosage | Varies by indication. Acromegaly: 50-100mcg three times daily initially, up to 500mcg TID. LAR (long-acting): 20-30mg IM every 4 weeks. | Intranasal: 100-500mcg 1-2 times daily. Lower doses than standard Semax may be effective due to enhanced potency. |
| Administration | Subcutaneous injection for immediate-release (between meals). Intramuscular for LAR depot form. Requires monitoring of gallbladder, glucose, and thyroid. | Intranasal spray is most common route. More stable than standard Semax. Often used for acute cognitive enhancement. |
| Side Effects | GI effects (diarrhea, nausea, abdominal pain), gallstones (up to 25% of long-term users), injection site reactions, and blood glucose changes. | Similar to Semax - possible irritability, hair shedding, or overstimulation. May have stronger effects than standard Semax. |
| Best For |